Read More

Novo Integrated Sciences Appoints Robert Oliva As New President, Succeeding Christopher David, Who Remains As Chief Operating Officer And As A Member Of Board Of Directors

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the "Company" or "Novo") announces today Mr. Robert Oliva has been appointed as the Company's new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors.

NVOS

Read More

Allogene Therapeutics To Restate Previously Filed Financial Statements Related To The December 2020 Formation Of The Allogene Overland Biopharm Joint Venture In Asia; No Impact On Cash, Cash Equivalents And Marketable Investments, Cash Runway Or Busine…

No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business Operations Company Targeting On or Before March 14, 2024 to File Amended Financial Statements and Report Fourth Quarter and

ALLO